Kalaris Therapeutics Inc
KLRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $46 | $12 | $12 | $25 |
| - Cash | $118 | $3 | $3 | $202 |
| + Debt | $0 | $0 | $3 | $30 |
| Enterprise Value | -$73 | $9 | $12 | -$147 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$59 | -$14 | -$15 | -$170 |
| % Margin | – | – | – | – |
| Net Income | -$59 | -$15 | -$15 | -$172 |
| % Margin | – | – | – | – |
| EPS Diluted | -11.73 | -42.089 | -50.621 | -63 |
| % Growth | 72.1% | 16.9% | 19.6% | – |
| Operating Cash Flow | -$68 | -$14 | -$10 | -$106 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$68 | -$14 | -$10 | -$106 |